{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:53:40Z","timestamp":1740164020223,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Konyang University Myung-gok Research Fund","award":["20-06"],"award-info":[{"award-number":["20-06"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1I1A3044287"],"award-info":[{"award-number":["2021R1I1A3044287"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to detect signals of adverse drug reactions (ADRs) associated with biological disease-modifying antirheumatic drugs (DMARDs) and targeted therapies in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients. Utilizing the KOrean College of Rheumatology BIOlogics &amp; Targeted Therapy Registry (KOBIO) data, we calculated relative risks, excluded previously reported drug-ADR pairs, and externally validated remaining pairs using US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and single centre\u2019s electronic health records (EHR) data. Analyzing data from 2279 RA and 1940 AS patients, we identified 35 significant drug-ADR pairs in RA and 26 in AS, previously unreported in drug labels. Among the novel drug-ADR pairs from KOBIO, 15 were also significant in the FAERS data. Additionally, 2 significant drug-laboratory abnormality pairs were found in RA using CDM MetaLAB analysis. Our findings contribute to the identification of 14 novel drug-ADR signals, expanding our understanding of potential adverse effects related to biological DMARDs and targeted therapies in RA and AS. These results emphasize the importance of ongoing pharmacovigilance for patient safety and optimal therapeutic interventions.<\/jats:p>","DOI":"10.1038\/s41598-024-52822-w","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:02:35Z","timestamp":1706785355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-1770","authenticated-orcid":false,"given":"M.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2204-9214","authenticated-orcid":false,"given":"C. I.","family":"Joung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-0608","authenticated-orcid":false,"given":"H.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6222","authenticated-orcid":false,"given":"C. C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-7913","authenticated-orcid":false,"given":"Y. S.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-9136","authenticated-orcid":false,"given":"Y. J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-0007","authenticated-orcid":false,"given":"S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-9307","authenticated-orcid":false,"given":"J. Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-6481","authenticated-orcid":false,"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"52822_CR1","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin, Y. J., Anzaghe, M. & Sch\u00fclke, S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9, 880. https:\/\/doi.org\/10.3390\/cells9040880 (2020).","journal-title":"Cells"},{"issue":"11","key":"52822_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","volume":"41","author":"Y Ingrasciotta","year":"2018","unstructured":"Ingrasciotta, Y. et al. Safety of biologics, including biosimilars: Perspectives on current status and future direction. Drug Saf. 41(11), 1013\u20131022 (2018).","journal-title":"Drug Saf."},{"key":"52822_CR3","unstructured":"Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions. (WHO, 2002). http:\/\/whqlibdoc.who.int\/hq\/2002\/WHO_EDM_QSM_2002.2.pdf"},{"issue":"6","key":"52822_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"RHB Meyboom","year":"1997","unstructured":"Meyboom, R. H. B. et al. Principles of signal detection in pharmacovigilance. Drug Saf. 16(6), 355\u2013365 (1997).","journal-title":"Drug Saf."},{"issue":"6","key":"52822_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"52822_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54(4), 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl","key":"52822_CR7","first-page":"1","volume":"21","author":"R Platt","year":"2012","unstructured":"Platt, R. et al. The U.S. Food and Drug Administration\u2019s Mini-Sentinel program: Status and direction. Pharmacoepidemiol. Drug Saf. 21(Suppl), 1\u20138 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"52822_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang, P. E. et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann. Intern. Med. 153(9), 600\u2013606 (2010).","journal-title":"Ann. Intern. Med."},{"key":"52822_CR9","volume-title":"Pharmacovigilance and Clinical Environment: Utilizing OMOP-CDM and OHDSI Software Stack to Integrate EHR Data","author":"VK Dimitriadis","year":"2021","unstructured":"Dimitriadis, V. K., Gavriilidis, G. I. & Natsiavas, P. Pharmacovigilance and Clinical Environment: Utilizing OMOP-CDM and OHDSI Software Stack to Integrate EHR Data (Stud Health Technol Inform IOS Press, 2021)."},{"key":"52822_CR10","doi-asserted-by":"publisher","first-page":"103119","DOI":"10.1016\/j.jbi.2019.103119","volume":"91","author":"Y Yu","year":"2019","unstructured":"Yu, Y. et al. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model. J. Biomed. Inform. 91, 103119. https:\/\/doi.org\/10.1016\/j.jbi.2019.103119 (2019).","journal-title":"J. Biomed. Inform."},{"issue":"1","key":"52822_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10799-015-0240-6","volume":"17","author":"MJ Rho","year":"2016","unstructured":"Rho, M. J. et al. Common data model for decision support system of adverse drug reaction to extract knowledge from multi-centre database. Inf. Technol. Manag. 17(1), 57\u201366 (2016).","journal-title":"Inf. Technol. Manag."},{"issue":"1","key":"52822_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12911-021-01520-y","volume":"21","author":"H Shin","year":"2021","unstructured":"Shin, H. et al. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources. BMC Med. Inform. Decis. Mak. 21(1), 159. https:\/\/doi.org\/10.1186\/s12911-021-01520-y (2021).","journal-title":"BMC Med. Inform. Decis. Mak."},{"issue":"5","key":"52822_CR13","first-page":"281","volume":"24","author":"JJ Mcneil","year":"2010","unstructured":"Mcneil, J. J., Piccenna, L., Ronaldson, K. & Ioannide-Demos, L. L. The value of patient-centred registries in phase IV drug surveillance. Pharmaceut. Med. 24(5), 281\u2013288 (2010).","journal-title":"Pharmaceut. Med."},{"issue":"4","key":"52822_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4078\/jrd.2021.28.4.176","volume":"28","author":"J Kim","year":"2021","unstructured":"Kim, J. et al. KOBIO, the first web-based korean biologics registry operated with a unified platform among distinct disease entities. J. Rheum Dis. 28(4), 176\u2013182 (2021).","journal-title":"J. Rheum Dis."},{"issue":"2","key":"52822_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie, J. L. Case-non-case studies: Principle, methods, bias and interpretation. Therapie 74(2), 225\u2013232 (2019).","journal-title":"Therapie"},{"issue":"4","key":"52822_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jamia\/ocw168","volume":"24","author":"S Lee","year":"2017","unstructured":"Lee, S. et al. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records. J. Am. Med. Inform. Assoc. 24(4), 697\u2013708 (2017).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"52822_CR17","doi-asserted-by":"publisher","first-page":"204209861986474","DOI":"10.1177\/2042098619864744","volume":"10","author":"A Bate","year":"2019","unstructured":"Bate, A., Hornbuckle, K., Juhaeri, J., Motsko, S. P. & Reynolds, R. F. Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Ther. Adv. Drug Saf. 10, 204209861986474. https:\/\/doi.org\/10.1177\/2042098619864744 (2019).","journal-title":"Ther. Adv. Drug Saf."},{"issue":"3","key":"52822_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben, M. & Zhou, X. Quantitative methods in pharmacovigilance. Drug Saf. 26(3), 159\u2013186 (2003).","journal-title":"Drug Saf."},{"issue":"11","key":"52822_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/pds.1248","volume":"15","author":"P Olivier","year":"2006","unstructured":"Olivier, P. & Montastruc, J. L. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol. Drug Saf. 15(11), 808\u2013812 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"52822_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/00002018-200629020-00008","volume":"29","author":"A Clarke","year":"2006","unstructured":"Clarke, A., Deeks, J. J. & Shakir, S. A. W. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf. 29(2), 175\u2013181 (2006).","journal-title":"Drug Saf."},{"issue":"3","key":"52822_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/amiajnl-2012-000930","volume":"20","author":"R Harpaz","year":"2013","unstructured":"Harpaz, R. et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J. Am. Med. Inform. Assoc. 20(3), 413\u2013419 (2013).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"52822_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbi.2017.10.013","volume":"76","author":"R Harpaz","year":"2017","unstructured":"Harpaz, R. et al. Toward multimodal signal detection of adverse drug reactions. J. Biomed. Inform. 76, 41\u201349 (2017).","journal-title":"J. Biomed. Inform."},{"issue":"10","key":"52822_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-015-0314-8","volume":"38","author":"Y Li","year":"2015","unstructured":"Li, Y., Ryan, P. B., Wei, Y. & Friedman, C. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 38(10), 895\u2013908 (2015).","journal-title":"Drug Saf."},{"issue":"1","key":"52822_CR24","doi-asserted-by":"publisher","first-page":"14045","DOI":"10.1038\/s41598-021-93522-z","volume":"11","author":"S Lee","year":"2021","unstructured":"Lee, S., Cha, J., Kim, J. Y., Son, G. M. & Kim, D. K. Detection of unknown ototoxic adverse drug reactions: An electronic healthcare record-based longitudinal nationwide cohort analysis. Sci. Rep. 11(1), 14045. https:\/\/doi.org\/10.1038\/s41598-021-93522-z (2021).","journal-title":"Sci. Rep."},{"issue":"7","key":"52822_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida, K., Solomon, D. H. & Kim, S. Y. Active-comparator design and new user design in observational studies. Nat. Rev. Rheumatol. 11(7), 437\u2013441 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"52822_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","volume":"44","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette, R. et al. Signal detection and methodological limitations in a real-world registry: Learnings from the evaluation of long-term safety analyses in PSOLAR. Drug Saf. 44(6), 699\u2013709 (2021).","journal-title":"Drug Saf."},{"key":"52822_CR27","doi-asserted-by":"publisher","first-page":"204209862090961","DOI":"10.1177\/2042098620909614","volume":"11","author":"MA Malikova","year":"2020","unstructured":"Malikova, M. A. Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance. Ther. Adv. Drug Saf. 11, 204209862090961. https:\/\/doi.org\/10.1177\/2042098620909614 (2020).","journal-title":"Ther. Adv. Drug Saf."},{"issue":"5","key":"52822_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Saf. 43(5), 479\u2013487 (2020).","journal-title":"Drug Saf."},{"issue":"3","key":"52822_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14712598.2018.1410134","volume":"18","author":"G Trifir\u00f2","year":"2018","unstructured":"Trifir\u00f2, G., Marcian\u00f2, I. & Ingrasciotta, Y. Interchangeability of biosimilar and biological reference product: Updated regulatory positions and pre- and post-marketing evidence. Expert Opin. Biol. Ther. 18(3), 309\u2013315 (2018).","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52822-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:14:33Z","timestamp":1706786073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52822-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52822"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52822-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2660"}}